Last SFr.88.95 CHF
Change Today -0.15 / -0.17%
Volume 4.2M
NOVN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
Frankfurt
As of 11:43 AM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Daniel L. Vasella M.D.

Honorary Chairman, Novartis AG
AgeTotal Calculated CompensationThis person is connected to 118 board members in 12 different organizations across 14 different industries.

See Board Relationships
61SFr.2,977,765

Background*

Dr. Daniel L. Vasella, also known as Dan, M.D., served as Chief Executive Officer of Novartis Consumer Health, Inc. since 1996. Dr. Vasella served as the Chief Executive Officer of Novartis AG. from 1996 to February 1, 2010 and served as its President since 1996. He served as Chief Executive Officer of Novartis Vaccines and Diagnostics, Inc. since 1996 and served as its Chairman since 1999. Dr. Vasella served as Chairman of Novartis from 1999 to February 2013 and as ...

Read Full Background

Corporate Headquarters*

Lichtstrasse 35
Basel, Basel-Stadt 4056

Switzerland

Phone: 41 61 324 11 11
Fax: --

Board Members Memberships*

Director
Former Director
Former Director
Chairman
Chairman of the Board
Member of Governing Board
Honorary Chairman
1995-N/A
Former Director
1996-N/A
Honorary Chairman
1996-Present
Chairman and Chief Executive Officer
1996-Present
Chairman
2002-Present
Independent Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee
2008-Present
Chairman, Chairman of Nominating/Corporate Governance Committee and Member of Compensation Committee
2012-Present
Director, Chairman of Audit & Compliance Committee, Member of Public Responsibility Committee and Member of Risk Committee
2014-Present
Director
2014-Present
Member of The Board of Directors

Education*

Honorary Doctorate
Universität Basel
MD 1979
University of Bern

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash CompensationSFr.2,280,617
Total Calculated CompensationSFr.2,977,765
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.88.95 CHF -0.15

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Alan George Lafley Chairman, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
$6.4M
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Serge Weinberg Chairman, Interim Chief Executive Officer, Chairman of Appointments & Governance Committee and Chairman of Strategy Committee
Sanofi
€700.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.